RFK Jr.
18 articles on RFK Jr., researched and written by the Shotlee Editorial Team from primary sources.
FDA to Review 7 Popular Peptides Touted for Weight Loss, Healing and Longevity
The FDA Pharmacy Compounding Advisory Committee is set to evaluate seven peptide substances currently available through the gray market. Experts weigh in on safety, efficacy, and future patient access.
7 min read
US Regulators Consider Controversial Peptides Backed by RFK Jr.
The US Food and Drug Administration is evaluating the use of seven peptides, increasingly marketed for wellness and medical conditions. This review comes amidst soaring popularity, celebrity endorsements, and significant debate over their safety and efficacy.
8 min read
Hims & Hers Q1 Earnings: What It Means for GLP-1 Access & Weight Loss
Hims & Hers reports Q1 results. See how financial growth and regulatory shifts affect patient access to semaglutide, tirzepatide, and peptide therapy.
7 min read
RFK Jr. and the Perils of Unapproved Peptides
The mantra 'once an accident, twice a coincidence, three times a trend' fuels bad journalism—and worse, risky medicine. A New Yorker investigation exposes clinics pushing unproven peptides for healing and longevity, backed by RFK Jr. While semaglutide proves the exception, most lack evidence and pose real harms.
5 min read
The Science Behind the Peptide Craze
Peptides are surging in popularity among influencers and biohackers for everything from injury recovery to youthful skin, but the science lags far behind the hype. With FDA bans on key ones like BPC-157 and potential changes ahead, here's what you need to know about their evidence, safety, and gray-market realities.
5 min read
RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
6 min read
What the War on Peptides Tells Us About Beauty's Future
Peptides are sweeping social media as injectables for clear skin, muscle gains, and fat loss, but a regulatory crackdown signals a war on unapproved versions. With FDA seizures, RFK Jr.'s advocacy, and black market persistence, what does this mean for beauty's future? Uncover the murky truths behind the hype.
5 min read
Americans Embrace Meat Industry's Protein Health Claims
More Americans are prioritizing meat for protein, with 75% seeing it as healthy—up from 64% in 2020. But experts like Tufts' Erin Hennessy caution against overfixating on meat amid industry pushes and RFK Jr.'s endorsements. Discover the health risks and smarter protein alternatives.
6 min read
RFK Jr. Misrepresents Ex-FDA Officials in Push to Lift Peptide Ban
Health Secretary RFK Jr. is pushing to lift the FDA's ban on 19 peptides used in compounding pharmacies, claiming the decision was illegal with no safety signals. But former FDA officials, including Janet Woodcock, say he misrepresents their views amid documented risks like immune reactions and trial fatalities. As demand surges via influencers, recent illnesses highlight the stakes in this regulatory battle.
6 min read
RFK Jr. Big Fan of Peptides: FDA Ban May Lift Soon
Health Secretary RFK Jr. revealed on Joe Rogan's podcast that the FDA may soon act on injectable peptides, which he supports making more accessible. Banned in 2023 for safety risks, these short amino acid chains show promise in anti-aging, muscle building, and more. Here's what peptides are and the debate surrounding them.
5 min read
Wellness Awaits RFK Jr.'s FDA Move on Peptides
Health Secretary RFK Jr. hinted at FDA easing restrictions on popular peptides like BPC-157 and ipamorelin during a Joe Rogan podcast. Wellness fans hope for access from ethical suppliers, but experts warn of black market dangers. Discover the regulatory shift's potential impact on peptide therapy.
5 min read
Hims & Hers Surges After RFK Jr. Pushes Peptide Access on Joe Rogan
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
5 min read
RFK Jr.'s Peptide Push: Risks of Bypassing FDA Trials
Robert F. Kennedy Jr., US health secretary nominee, wants to open sales of restricted injectable peptides, fitting his Make America Healthy Again agenda. While some peptides show promise, the FDA halted 17 in 2023 due to safety risks—without trials, anecdote isn't evidence. This editorial warns against sidelining regulation for wellness hucksters.
4 min read
Supplement Makers Push FDA to Allow Peptides, New Ingredients
Makers of dietary supplements are pressing the FDA to permit peptides, probiotics, and other trendy ingredients not traditionally found in food. A pivotal public meeting highlighted industry pleas, RFK Jr.'s support, and warnings from consumer advocates. Here's what to know about this regulatory push reshaping the $100B+ supplement market.
6 min read
Supplement Makers Push FDA to Allow Peptides and New Ingredients
Dietary supplement makers are pressing the FDA to broaden ingredient criteria, potentially greenlighting peptides and probiotics not traditionally found in food. A key public meeting highlighted industry pleas under RFK Jr.'s health leadership, sparking debates on safety and oversight. Here's what this means for the booming wellness market.
6 min read
Peptide Gold Rush: Deregulation Set to Supercharge Shadow Industry
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
5 min read
RFK Jr. Plans to Unban 14 FDA-Banned Peptides, Tells Joe Rogan
RFK Jr. revealed on the Joe Rogan Experience his intent to lift FDA restrictions on 14 banned peptides from compounding pharmacies. This reversal addresses the late 2023 Category 2 list ban amid safety concerns and black market shifts. Patients and wellness advocates await formal decisions in coming weeks.
5 min read
BPC-157: Hype, Science, and Safety Risks Explained
BPC-157 promises rapid healing for injuries and inflammation, but nearly all evidence comes from animal studies with scant human trials. As hype surges in wellness circles and amid policy shifts, experts urge caution due to safety unknowns and FDA prohibitions. This guide breaks down the science, risks, and what patients need to know.
5 min read